About Tirzepatide
Tirzepatide is a synthetic peptide that acts as a dual agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It was developed as a treatment for type 2 diabetes and obesity. Compared to GLP-1 single agonists, the dual mechanism of Tirzepatide provides enhanced metabolic effects.
ShiLai™ Healthcare manufactures Tirzepatide by solid-phase peptide synthesis (SPPS) with RP-HPLC purification and LC-MS identity confirmation on every batch.
Tirzepatide vs Retatrutide
| Parameter | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + Glucagon (triple agonist) |
| Amino acids | 39 | 39 |
| Mechanism | Dual incretin agonism | Triple incretin/glucagon agonism |
B2B OEM Projects Only
We are currently not accepting individual or retail customer orders.
Chat on WhatsApp